Medpace Holdings is a clinical research organization, or CRO. The simplest way to understand a CRO is to think of it as a general contractor for clinical trials.Read more
Medpace is riding a wave of demand for clinical trials, but some of its recent momentum may come from projects that bring in lots of reimbursed costs without boosting profits much. With client funding still shaky and competition heating up, the next phase could test whether this growth holds up—or fades as the work mix and costs shift.Read more
Medpace could benefit as more drugmakers hand off clinical trial work and as newer, more flexible trial designs become the norm. The catch is that it relies on a small group of customers and faces rising rule-making and fast-moving tech changes that could squeeze future growth.Read more
Medpace looks like it’s benefiting from a rush of fast-moving work right now, but that boost may fade as projects and client budgets shift. If smaller biotech customers pull back or costs keep climbing, today’s strong results could prove less stable than they seem.Read more
No trending discussion available.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
